Alexia Iasonos

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma
    Alexia Iasonos
    Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
    Cancer 119:1816-22. 2013
  2. ncbi Interplay of priors and skeletons in two-stage continual reassessment method
    Alexia Iasonos
    Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA
    Stat Med 31:4321-36. 2012
  3. ncbi The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials
    Alexia Iasonos
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Cancer Res 18:5179-87. 2012
  4. ncbi Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remission
    Alexia Iasonos
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Gynecol Cancer 22:63-9. 2012
  5. ncbi How to build and interpret a nomogram for cancer prognosis
    Alexia Iasonos
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 E 63rd St, 3rd Floor, New York, NY 10021, USA
    J Clin Oncol 26:1364-70. 2008
  6. ncbi A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies
    Alexia Iasonos
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Trials 5:465-77. 2008
  7. ncbi Estimating the dose-toxicity curve in completed phase I studies
    Alexia Iasonos
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Stat Med 30:2117-29. 2011
  8. ncbi Incorporating lower grade toxicity information into dose finding designs
    Alexia Iasonos
    Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Trials 8:370-9. 2011
  9. ncbi The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum
    Oliver Zivanovic
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:351-7. 2010
  10. ncbi Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 69:255-9. 2007

Detail Information

Publications62

  1. ncbi External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma
    Alexia Iasonos
    Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
    Cancer 119:1816-22. 2013
    ..By using an independent, pooled, multi-institutional, international patient cohort, the authors validated a recently proposed ULMS nomogram...
  2. ncbi Interplay of priors and skeletons in two-stage continual reassessment method
    Alexia Iasonos
    Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA
    Stat Med 31:4321-36. 2012
    ..In general, because this information is not available, we recommend that the design of two-stage trials utilize stage 1 data to establish a skeleton...
  3. ncbi The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials
    Alexia Iasonos
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Cancer Res 18:5179-87. 2012
    ....
  4. ncbi Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remission
    Alexia Iasonos
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Gynecol Cancer 22:63-9. 2012
    ..We illustrate how the duration of second-line therapy (SLT), the time on the investigational therapy (IT), and patient enrollment plan can affect efficacy measures from maintenance trials and might result in underpowered studies...
  5. ncbi How to build and interpret a nomogram for cancer prognosis
    Alexia Iasonos
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 E 63rd St, 3rd Floor, New York, NY 10021, USA
    J Clin Oncol 26:1364-70. 2008
    ..This guide provides a nonstatistical audience with a methodological approach for building, interpreting, and using nomograms to estimate cancer prognosis or other health outcomes...
  6. ncbi A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies
    Alexia Iasonos
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Trials 5:465-77. 2008
    ..From a practical perspective, clinicians are interested in designs that can estimate the MTD using fewer patients for a fixed number of doses, or can test more dose levels for a given sample size...
  7. ncbi Estimating the dose-toxicity curve in completed phase I studies
    Alexia Iasonos
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Stat Med 30:2117-29. 2011
    ..Confidence intervals around the toxicity probabilities at each dose level are estimated using the cumulative toxicity data. A programming code is included...
  8. ncbi Incorporating lower grade toxicity information into dose finding designs
    Alexia Iasonos
    Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Trials 8:370-9. 2011
    ..Some authors have argued that it may be more appropriate to consider a polytomous rather than dichotomous response...
  9. ncbi The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum
    Oliver Zivanovic
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:351-7. 2010
    ....
  10. ncbi Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 69:255-9. 2007
    ..A unifying feature of these malignancies is their aggressive course and poor outcome with standard chemotherapeutic regimens. Given the rarity of these tumors, no prospective data are available to guide management...
  11. ncbi Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer
    Arjun V Balar
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 31:724-30. 2013
    ..This trial evaluated the efficacy and safety of bevacizumab with GCa in advanced UC...
  12. ncbi The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment
    Roisin O'Cearbhaill
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:326-31. 2010
    ....
  13. ncbi Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer
    Oliver Zivanovic
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Gynecol Oncol 115:209-14. 2009
    ..To analyze whether serum CA-125 response to cytoreductive surgery before initiation of postoperative chemotherapy is associated with progression-free survival (PFS) in patients with stage IIIC ovarian carcinoma...
  14. ncbi A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma
    Oliver Zivanovic
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 118:660-9. 2012
    ..The objective of the current study was to develop and validate a novel, clinically relevant, individualized prognostic model for patients with uterine LMS...
  15. ncbi Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy
    Ethan Basch
    Department of Epidemiology and Biostatistics, and the Office of the Physician in Chief, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:5374-80. 2007
    ..In cancer treatment trials, clinicians traditionally report patient toxicity symptoms. Alternatively, patients could provide this information directly...
  16. ncbi A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma
    Vicky Makker
    Memorial Sloan Kettering Cancer Center Department of Medicine, Gynecologic Medical Oncology Service, New York, NY, USA
    Gynecol Oncol 111:249-54. 2008
    ..To determine the progression-free survival (PFS) and overall survival (OS) in a cohort of patients who received either platinum-based chemotherapy with or without radiation therapy (pelvic or WAI), or RT alone...
  17. ncbi Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 109:549-55. 2007
    ..The safety and activity of a dose-dense carboplatin-based regimen in this patient population were explored...
  18. ncbi Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium
    Matthew I Milowsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 27:4062-7. 2009
    ..This study sought to evaluate the efficacy and to additionally define toxicity...
  19. ncbi Renal cell carcinoma in young and old patients--is there a difference?
    R Houston Thompson
    Department of Surgery Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 180:1262-6; discussion 1266. 2008
    ..We reviewed our experience with young patients with renal cell carcinoma and compared them to their older counterparts...
  20. ncbi Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems
    Oliver Zivanovic
    Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 27:2066-72. 2009
    ..We aimed to determine whether the American Joint Committee on Cancer (AJCC) soft tissue sarcoma (STS) staging system is more accurate in predicting progression-free survival (PFS) and overall survival (OS)...
  21. ncbi Consolidation strategies in ovarian cancer: observations for future clinical trials
    Paul Sabbatini
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 116:66-71. 2010
    ..CONCLUSION.: Preliminary benchmarks for efficacy endpoints are suggested for future consolidation trials of patients in cCR. However, the suggested strategies will require validation in randomized trials and larger data sets...
  22. ncbi Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors
    Karin K Shih
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 119:270-3. 2010
    ..The objective of this study was to evaluate patterns of recurrence and prognostic factors as well as the role of adjuvant chemotherapy in stage II-IV ovarian SBT...
  23. ncbi Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study
    Martee L Hensley
    Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York 10065, USA
    Cancer 118:2403-10. 2012
    ..In this study, the authors assessed the efficacy of eribulin in platinum-resistant and platinum-sensitive recurrent ovarian cancer...
  24. ncbi Treatment patterns of FIGO Stage IB2 cervical cancer: a single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapy
    Oliver Zivanovic
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Gynecol Oncol 111:265-70. 2008
    ..The treatment of FIGO stage IB2 cervical cancer is controversial. Our aim was to assess treatment patterns, outcomes, and complications in patients with stage IB2 cervical cancer...
  25. ncbi Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors
    Roisin O'Cearbhaill
    Department of Medicine, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:424-9. 2010
    ..Aromatase inhibitors are sometimes used in the treatment of selected patients with uterine leiomyosarcoma (LMS), but there are few data assessing the efficacy of aromatase inhibitors in this setting...
  26. ncbi The revised 2009 FIGO staging system for endometrial cancer: should the 1988 FIGO stages IA and IB be altered?
    Nadeem R Abu-Rustum
    Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Gynecol Cancer 21:511-6. 2011
    ..We sought to describe the overall survival (OS) of women with stage I endometrial cancer and examine how the estimated stage-specific OS is altered in the 2009 system...
  27. ncbi Impact of operative start time on surgical outcomes in patients undergoing primary cytoreduction for advanced ovarian cancer
    Edward J Tanner
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 126:58-63. 2012
    ..To evaluate the impact of operative start time (OST) on surgical outcomes in patients with advanced ovarian cancer...
  28. ncbi Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer
    Jason A Konner
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 29:4662-8. 2011
    ..Bevacizumab prolongs progression-free survival (PFS) when included in first-line IV chemotherapy. In this study, the safety and feasibility of adding bevacizumab to a first-line IP regimen were assessed...
  29. ncbi A 2-year prospective study assessing the emotional, sexual, and quality of life concerns of women undergoing radical trachelectomy versus radical hysterectomy for treatment of early-stage cervical cancer
    Jeanne Carter
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 119:358-65. 2010
    ..To prospectively assess and describe the emotional, sexual, and QOL concerns of women with early-stage cervical cancer undergoing radical surgery...
  30. ncbi Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma
    David J Gallagher
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 115:5193-201. 2009
    ..The objective of this study was to evaluate the feasibility and survival impact of adjuvant, sequential chemotherapy in patients with high-risk UC...
  31. ncbi Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes
    Ethan Basch
    Health Outcomes Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd St, New York, NY 10065, USA
    J Natl Cancer Inst 101:1624-32. 2009
    ..Patient self-reporting has been proposed as an additional data source, but the implications of such a shift are not understood...
  32. ncbi The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer
    Oliver Zivanovic
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave New York, NY 10021, USA
    Gynecol Oncol 108:287-92. 2008
    ..To analyze the impact of bulky upper abdominal disease (UAD) cephalad to the greater omentum on surgical outcomes for patients with stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal carcinoma...
  33. ncbi Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset
    Karuna Garg
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 33:1869-77. 2009
    ..Although young EC patients are at increased risk for synchronous endometrioid ovarian carcinomas, this does not seem to be associated with MMR loss...
  34. ncbi Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer
    Destin Black
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 109:39-42. 2008
    ..p.) chemotherapy for ovarian cancer. Because of recent reports of higher rates of catheter complications, we performed this study to update our experience with the fenestrated catheter...
  35. ncbi BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer
    Rachel N Grisham
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 119:548-54. 2013
    ..In the current study, the authors sought to determine whether BRAF or KRAS mutation status was associated with disease stage and/or histology in patients with SB and LGS ovarian cancer...
  36. ncbi Effect of perioperative venous thromboembolism on survival in ovarian, primary peritoneal, and fallopian tube cancer
    Destin Black
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 107:66-70. 2007
    ..The purpose of this study was to describe the overall survival of patients with ovarian, primary peritoneal, and fallopian tube cancers treated for VTE within 30 days of initial surgery...
  37. ncbi A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission
    Douglas Levine
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 110:2448-56. 2007
    ..The current study was conducted to determine the effect of goserelin and bicalutamide on progression-free survival (PFS) in patients with epithelial ovarian cancer who were in second or greater complete disease remission...
  38. ncbi CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy
    Margrit M Juretzka
    Gynecology Oncology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 104:176-80. 2007
    ..A secondary objective was to assess the relationship of CA125 level to PFS...
  39. ncbi Colorectal stents for palliation of large-bowel obstructions in recurrent gynecologic cancer: an updated series
    Aileen Caceres
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 108:482-5. 2008
    ..Our objective was to review and update our experience with colonic stent placement for patients presenting with a large-bowel obstruction due to recurrent gynecologic malignancy...
  40. ncbi Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma?
    Nadeem R Abu-Rustum
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Obstet Gynecol 198:457.e1-5; discussion 457.e5-6. 2008
    ..The objective of the study was to evaluate whether surgical removal of regional lymph nodes influences the overall survival of women with endometrial carcinoma...
  41. ncbi Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma
    John Gerecitano
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York 10065, USA
    Clin Cancer Res 17:2493-501. 2011
    ....
  42. ncbi Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience
    Rachel Nicole Grisham
    Gynecologic Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Gynecol Cancer 22:807-11. 2012
    ..We performed a retrospective study to determine the progression-free survival and response rate of endometrial cancer patients treated with gemcitabine at Memorial Sloan-Kettering Cancer Center...
  43. ncbi Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer
    David M Hyman
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Cancer 118:3703-9. 2012
    ..The objective of the current study was to examine whether BRCA1-associated and BRCA2-associated ovarian cancers were associated with different outcomes...
  44. ncbi Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer
    Catherine S M Diefenbach
    Gynecologic Medical Oncology, Department of Medicine, Howard 903, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 104:435-42. 2007
    ..In this study, we examined the frequency of serum elevation as well as the diagnostic and prognostic significance of this serum marker in endometrial cancer...
  45. ncbi External validation of a nomogram predicting overall survival of patients diagnosed with endometrial cancer
    Stephan Polterauer
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 125:526-30. 2012
    ..The aim of this study was to test the validity of the MSKCC endometrial cancer nomogram using an independent, external patient cohort...
  46. ncbi Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer
    Paul J Sabbatini
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:4170-7. 2007
    ....
  47. ncbi Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers
    David M Hyman
    Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 123:196-9. 2011
    ..To evaluate the efficacy of topoisomerase I inhibitor, topotecan, in patients with recurrent BRCA+ versus BRCA- ovarian, fallopian tube, and primary peritoneal carcinomas...
  48. ncbi Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16
    Thapi Dharma Rao
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Appl Immunohistochem Mol Morphol 18:462-72. 2010
    ..Development of such antibodies may be useful for the characterization of MUC16 biology and allow for future studies in targeted therapy and diagnostics...
  49. ncbi Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature
    Lisa Dos Santos
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 105:321-4. 2007
    ..The prognosis is generally poor when disease has spread beyond the ovary. We conducted this study to review our experience with this disease and describe our current treatment modality...
  50. ncbi Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission
    Catherine S M Diefenbach
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 14:2740-8. 2008
    ..In this study, we describe the effects of vaccination with the HLA-A*0201-restricted NY-ESO-1b peptide on patients with epithelial ovarian cancer in high-risk first remission...
  51. ncbi Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy
    Andrea B Apolo
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Natl Cancer Inst 105:499-503. 2013
    ..69) and 0.58 (95% CI = 0.52 to 0.65), respectively, with superiority of the four-variable model compared with the MSKCC risk-score model for OS (the U statistic and its standard deviation were used to calculate the two-sided P = .02)...
  52. ncbi Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Paul Sabbatini
    Memorial Sloan-Kettering Cancer Center, New York, New York, Franklin Square Hospital, Baltimore, MD, USA, and University of Marburg, Germany
    Clin Cancer Res 12:5503-10. 2006
    ..CONCLUSIONS: Immunization with abagovomab is well tolerated and induced robust Ab3 responses at the two doses and routes tested. A phase III randomized study with abagovomab (2.0 mg s.c.) is warranted...
  53. ncbi Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma
    Craig H Moskowitz
    Departments of Medicine, Radiology, Pathology, and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 28:1896-903. 2010
    ..Outside of a clinical trial, we recommend biopsy confirmation of an abnormal interim FDG-PET scan before changing therapy...
  54. ncbi The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center
    Nadeem R Abu-Rustum
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 103:714-8. 2006
    ..To describe the incidence of symptomatic postoperative lower-extremity lymphedema in women treated for uterine corpus cancer, and to evaluate its relationship to regional lymph node removal and postoperative therapy...
  55. ncbi Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities
    Ethan Basch
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Am Med Inform Assoc 14:264-8. 2007
    ..Ongoing multi-center research will evaluate the impact of this approach on clinical and administrative outcomes...
  56. ncbi Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study
    Ethan Basch
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet Oncol 7:903-9. 2006
    ..We aimed to compare the reporting of symptom severity reported by patients and clinicians...
  57. ncbi Predicting the histology of renal masses using preoperative Doppler ultrasonography
    Ganesh V Raj
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 177:53-8. 2007
    ..Since conventional clear cell carcinomas are highly vascular, we used preoperative color and/or power Doppler ultrasonography to evaluate the association between vascular flow in a renal mass and surgical pathology...
  58. ncbi Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer
    Ganesh V Raj
    Department of Urology, 353 E 68th St, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:3095-100. 2006
    ..Methodology for determining CrCl and/or renal eligibility for cisplatin-based chemotherapy in patients with bladder cancer should be re-examined...
  59. ncbi A pilot study using the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) as a clinical care tool to identify lower extremity lymphedema in gynecologic cancer survivors
    Jeanne Carter
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 117:317-23. 2010
    ..This study aimed to determine the feasibility and efficacy of using the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) as a symptom scale for lymphedema of the lower extremity (LLE)...
  60. ncbi Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival
    Catherine S M Diefenbach
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    Cancer 107:1511-9. 2006
    ..LPAAT-beta is an intriguing prognostic tool for the identification of high-risk EOC and a potential target for directed therapy that warrants further study...
  61. ncbi Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Joan and Sanford Weill Medical College of Cornell University, New York, NY 10021, USA
    Invest New Drugs 25:265-70. 2007
    ..The purpose of this single-center phase II study was to determine the activity of pemetrexed administered as second-line therapy in patients with advanced urothelial carcinoma...
  62. ncbi Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials
    Michelle L Harrison
    Department of Gynaecology, The Royal Marsden Hospital, London, UK
    Gynecol Oncol 106:469-75. 2007
    ....